<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Therapeutic resistance remains the most challenging aspect of treating <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Raf kinase inhibitory protein (RKIP) emerged as a molecule capable of sensitizing cancerous cells to radio- and chemotherapy </plain></SENT>
<SENT sid="2" pm="."><plain>Moreover, this small evolutionary conserved molecule, endows significant resistance to <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> therapy when its expression is reduced or lost </plain></SENT>
<SENT sid="3" pm="."><plain>RKIP has been shown to inhibit the Raf-MEK-ERK, NFκB, GRK and activate the GSK3β signaling pathways </plain></SENT>
<SENT sid="4" pm="."><plain>Inhibition of Raf-MEK-ERK and NFκB remains the most prominent pathways implicated in the sensitization of cells to therapeutic drugs </plain></SENT>
<SENT sid="5" pm="."><plain>Our purpose was to identify a possible link between RKIP-KEAP 1-NRF2 and drug resistance </plain></SENT>
<SENT sid="6" pm="."><plain>To that end, RKIP-KEAP 1 association was tested in human <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> tissues using immunohistochemistry </plain></SENT>
<SENT sid="7" pm="."><plain>RKIP miRNA silencing and its inducible overexpression were employed in HEK-293 immortalized cells, HT29 and HCT116 <z:hpo ids='HP_0003003'>colon cancer</z:hpo> cell lines to further investigate our aim </plain></SENT>
<SENT sid="8" pm="."><plain>We show that RKIP enhanced Kelch-like ECH-associated protein1 (KEAP 1) stability in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> tissues and HT29 <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell line </plain></SENT>
<SENT sid="9" pm="."><plain>RKIP silencing in immortalized HEK-293 cells (termed HEK-499) correlated significantly with KEAP 1 protein degradation and subsequent NRF2 <z:mp ids='MP_0002555'>addiction</z:mp> in these cells </plain></SENT>
<SENT sid="10" pm="."><plain>Moreover, RKIP <z:mpath ids='MPATH_63'>depletion</z:mpath> in HEK-499, compared to control cells, bestowed resistance to supra physiological levels of <z:chebi fb="0" ids="16240">H(2)O(2)</z:chebi> and <z:chebi fb="2" ids="27899">Cisplatin</z:chebi> possibly by upregulating NF-E2-related nuclear factor 2 (NRF2) responsive genes </plain></SENT>
<SENT sid="11" pm="."><plain>Similarly, we observed a direct correlation between the extent of <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, after treatment with Adriamycin, and the expression levels of RKIP/KEAP 1 in HT29 but not in HCT116 <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells </plain></SENT>
<SENT sid="12" pm="."><plain>Our data illuminate, for the first time, the NRF2-KEAP 1 pathway as a possible target for personalized therapeutic intervention in RKIP depleted <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
</text></document>